Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States.
Colin EdgertonAndrew FrickSimon HelfgottKent Kwas HustonJasvinder A SinghPatrick ZuegerSamuel I AnyanwuPankaj PatelNehad SolomanPublished in: ACR open rheumatology (2024)
In clinical practice, over half of patients with RA initiating a first-line TNFi did not have baseline disease activity assessments. Many patients cycled through TNFi despite citing lack of efficacy as the most common reason for discontinuation. Consistent, objective monitoring of treatment response and timely switch to effective therapy is needed in patients with RA.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- ankylosing spondylitis
- rheumatoid arthritis patients
- clinical practice
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- juvenile idiopathic arthritis
- palliative care
- chronic kidney disease
- stem cells
- prognostic factors
- bone marrow
- idiopathic pulmonary fibrosis
- chronic pain
- combination therapy